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A B S T R A C T
Objective: To characterize individual and group-level neuroimaging ﬁndings in patients at risk for Chronic
Traumatic Encephalopathy (CTE).
Methods: Eleven male patients meeting criteria for Traumatic Encephalopathy Syndrome (TES, median age: 64)
underwent neurologic evaluation, 3-Tesla MRI, and PET with [18F]-Flortaucipir (FTP, tau-PET) and [11C]-
Pittsburgh compound B (PIB, amyloid-PET). Six patients underwent [18F]-Fluorodeoxyglucose-PET (FDG, glu-
cose metabolism). We assessed imaging ﬁndings at the individual patient level, and in group-level comparisons
with modality-speciﬁc groups of cognitively normal older adults (CN). Tau-PET ﬁndings in patients with TES
were also compared to a matched group of patients with mild cognitive impairment or dementia due to
Alzheimer's disease (AD).
Results: All patients with TES sustained repetitive head injury participating in impact sports, ten in American
football. Three patients met criteria for dementia and eight had mild cognitive impairment. Two patients were
amyloid-PET positive and harbored the most severe MRI atrophy, FDG hypometabolism, and FTP-tau PET
binding. Among the nine amyloid-negative patients, tau-PET showed either mildly elevated frontotemporal
binding, a “dot-like” pattern, or no elevated binding. Medial temporal FTP was mildly elevated in a subset of
amyloid-negative patients, but values were considerably lower than in AD. Voxelwise analyses revealed a
convergence of imaging abnormalities (higher FTP binding, lower FDG, lower gray matter volumes) in fronto-
temporal areas in TES compared to controls.
Conclusions: Mildly elevated tau-PET binding was observed in a subset of amyloid-negative patients at risk for
CTE, in a distribution consistent with CTE pathology stages III-IV. FTP-PET may be useful as a biomarker of tau
pathology in CTE but is unlikely to be sensitive to early disease stages.
1. Introduction
Chronic Traumatic Encephalopathy (CTE) is a neurodegenerative
tauopathy associated with repetitive head impacts (RHI) (Mez et al.,
2017; McKee et al., 2013). The post-mortem diagnosis of CTE is based
on the identiﬁcation of aggregated hyper-phosphorylated tau (p-tau) in
neurons and astrocytes in a characteristic distribution in perivascular
spaces and in the depth of cortical sulci (Mez et al., 2017; McKee et al.,
2013; Baugh et al., 2014). Co-pathologies, including aggregated amy-
loid-beta (Aβ), alpha-synuclein, and transactive response DNA binding
protein 43 kilodalton inclusions, are often found in advanced disease
stages. Non-speciﬁc macroscopic features include gray matter atrophy,
ventricular enlargement and septal abnormalities (McKee et al., 2013).
Traumatic Encephalopathy Syndrome (TES) deﬁnes a clinical syn-
drome associated with RHI (Reams et al., 2016; Montenigro et al.,
2014; Jordan, 2013; Victoroﬀ, 2013). Clinical features include
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behavioral, mood, cognitive and motor changes (Mez et al., 2017;
McKee et al., 2013; Baugh et al., 2014; Gardner et al., 2015) that often
present years after exposure to head trauma. Provisional research di-
agnostic criteria for TES have been proposed by several groups, how-
ever, there are no consensus criteria to date, and eﬀorts are ongoing to
validate clinical features that best predict underlying CTE neuro-
pathology (Mez et al., 2015; Diagnose-CTE Research).
The diagnosis of CTE can be only made postmortem. Diagnosing
CTE during life is challenging due to the clinical diversity of TES, the
lack of veriﬁed consensus criteria and the lack of validated in-vivo
biomarkers (Gardner et al., 2015). Adding neuroimaging biomarkers
that identify the disease's core pathologic features may improve in-vivo
diagnostic abilities. MRI and ﬂudeoxyglucose positron emission tomo-
graphy (FDG-PET) can detect structural and functional neurodegen-
erative changes respectively, while radiotracers speciﬁc for tau and Aβ
could be helpful in detecting the molecular pathology of CTE and ex-
cluding underlying Alzheimer's disease (AD). Previous studies utilizing
structural MRI found higher rates and larger size of cavum septum
pellucidum (CSP) as well as more pronounced atrophy in patients at
risk for CTE compared with aged matched controls (Little et al., 2014;
Orrison et al., 2009; Gardner et al., 2016; Koerte et al., 2015). In ad-
dition, hypometabolism on FDG-PET was reported in at-risk patients
(Gardner et al., 2015; Bang et al., 2015; Provenzano et al., 2010;
Peskind et al., 2011). A recent study comparing Aβ (18F-ﬂorbetapir) and
tau (18F-ﬂortaucipir, FTP) PET ﬁndings in 26 symptomatic retired
professional American football players versus 31 matched controls
found higher FTP retention in bilateral frontotemporal and left parietal
lobes in patients at risk for CTE (Stern et al., 2019). Amyloid positivity
was not signiﬁcantly diﬀerent between the groups. Other studies uti-
lizing Aβ and tau-PET are limited to case reports and small case series
(Mitsis et al., 2014; Dickstein et al., 2016; Barrio et al., 2015;
Omalu et al., 2017).
The goal of this study was to characterize multi-modal brain ima-
ging ﬁndings in patients meeting TES criteria who are at risk for CTE.
Findings were compared to cognitively normal controls without known
exposure to RHI, and tau-PET ﬁndings were compared to patients with
AD. We hypothesized that MRI and FDG-PET would identify neurode-
generative changes in the frontotemporal cortex, while tau-PET signal
would be elevated in similar regions in patients with and without ele-
vated Aβ-PET signal.
2. Methods
2.1. Patients with TES
We recruited consecutive patients exposed to RHI (Table 1) who
presented with neurologic complaints at the University of California
San Francisco (UCSF) Memory and Aging Center between August 2014
and October 2017. Patients were required to meet criteria for TES as
proposed by Montenigro et-al5: history of multiple head impacts, no
other neurological disorder that likely accounts for all clinical features,
clinical symptoms present for more than 12 months, at least one core
symptom including cognitive, mood or behavior, and two supportive
features. To avoid circularity, we did not include tau-PET results as one
of the factors considered for TES diagnosis. As part of the research
evaluation, all participants underwent a detailed history and physical
examination by a neurologist, a structured caregiver interview by a
nurse, a battery of neuropsychological tests (Ossenkoppele et al., 2016),
and multimodal brain imaging, including structural 3T MRI, 11C-Pitts-
burgh compound B (PIB) Aβ-PET and 18F-Flortaucipir (FTP) tau-PET. A
subset of patients also underwent 18F-FDG-PET. The average intervals
between PET and MRI, PET and clinical testing, and MRI and clinical
testing were 20 days (range: 1–69), 21 days (range: 1–68), and 6 days
(range: 0–63), respectively.
2.2. Control groups
Imaging ﬁndings in patients with TES were compared to ﬁndings in
cognitively normal controls (CN). FTP-PET in patients with TES was
additionally compared to FTP in patients with AD. CN without known
history of RHI were recruited from an aging cohort at UCSF
(Staﬀaroni et al., 2018) for MRI and FDG, and from the Berkeley Aging
Cohort Study (BACS) for all PET modalities (Maass et al., 2017). In
order to optimally match for scanner, demographics and clinical char-
acteristics, we compared each imaging modality in the TES group to a
distinct control group (Table 2):
2.2.1. FTP-PET control groups
The FTP-PET healthy control group consisted of 67 Aβ-PET negative
individuals. Due to limited availability of male only FTP data, both
males and females were included. FTP controls were matched to the
TES patients for education and age range. However, due to limitations
of available data, the FTP controls were older than the TES group
(median age at PET: 76 in the CN group versus 64 in the TES group).
The FTP-PET disease control group consisted of 22 males and fe-
males (due to limited availability of male only FTP data) patients from
UCSF research cohorts meeting clinical criteria for mild cognitive im-
pairment (MCI) or dementia due to AD (McKhann et al., 2011) with
positive Aβ-PET and no known history of RHI. AD patients were mat-
ched on age and education to the TES patients (Mann-Whitney U-tests,
p>0.56). Patients with probable AD were classiﬁed as MCI or dementia
stage based on the Clinical Dementia Rating (CDR) (Morris, 1993).
2.2.2. The FDG-PET control group consisted of 30 αβ-negative males
matched on age and education to the TES group (Mann-Whitney U-tests,
p> 0.08).
##
2.2.3. MRI control groups
The healthy control group for group voxel-wise analysis consisted of
54 males matched on age and education to the TES group (Mann-
Whitney U-tests, p>0.08) and scanned on the same two MRI scanners
as the TES patients. Amyloid status was not available for this group.
For individual atrophy level assessment, w-maps (see below) were
computed from a healthy control group dataset published by
Potvin et al. (2017).
2.3. Patients and study participants
Written informed consent was obtained from all participants or their
surrogate decision makers. The UCSF, University of California Berkeley
and Lawrence Berkeley National Laboratory (LBNL) institutional review
boards for human research approved the study.
2.4. Assessment of neuropsychological test scores
The neuropsychological battery included: the California verbal
learning test (second edition) (Delis, 2000) and a test of recall of the
Benson ﬁgure (Kramer et al., 2003) to assess episodic memory; forward
and backward digit span (Rabinovici et al., 2015), Stroop color naming
and inhibition (Stroop, 1935), modiﬁed Trail-making (Kramer et al.,
2003), design ﬂuency (Homack et al., 2005), phonemic ﬂuency (words
beginning with the letter ‘D’/minute) (Kramer et al., 2003), and se-
mantic ﬂuency (animals/minute) (Kramer et al., 2003) to assess ex-
ecutive functioning; the 15-item Boston Naming Test (Homack et al.,
2005) to assess language; the Benson ﬁgure copy to asses visuospatial
skills; and the Geriatric Depression Scale (GDS) (Yesavage et al., 1982).
Neuropsychological test scores were standardized (z-transformed)
based on age- and education-matched healthy control performance. We
used a cutoﬀ score of −1.5≤ z ≤ −1.1 to designate mild clinical
impairment and Z ≤ −1.5 to designate moderate to severe clinical
O.H. Lesman-Segev, et al. NeuroImage: Clinical 24 (2019) 102025
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impairment.
2.5. Neuroimaging acquisition
2.5.1. MRI
Structural T1-weighted MRI was acquired using magnetization
prepared rapid acquisition gradient echo (MPRAGE) sequence on a 3T
Siemens Tim Trio scanner (N=5) or 3T Siemens MAGNETOM Prisma
(Siemens Medical Systems) (N=6) at the UCSF neuroimaging center as
previously described (Ossenkoppele et al., 2016). Both scanners had
very similar acquisition parameters (sagittal slice orientation; slice
thickness= 1.0 mm; slices per slab=160; in-plane resolu-
tion=1.0×1.0 mm; matrix= 240×256; repetition time= 2,300 ms;
inversion time= 900 ms; ﬂip angle= 9°), although echo time diﬀered
slightly (Trio: 2.98 ms; Prisma: 2.90 ms).
2.5.2. PET
PIB-, FTP-, and FDG-PET scans were performed at LBNL on a
Siemens Biograph 6 Truepoint PET/CT scanner in 3D acquisition mode.
All PET scans were acquired within a short time period. PIB and FTP
were typically acquired sequentially on the same day, and FDG was
acquired at least 24 h following previous PET. Range between ﬁrst and
last PET scans was 0 (if only PIB and FTP were acquired and both on the
same day) to 47 days. A low-dose CT scan was performed for attenua-
tion correction prior to all scans. PIB and FTP were synthesized at the
LBNL Biomedical Isotope Facility. FDG was purchased from a com-
mercial vendor (IBA Molecular). Injected doses were approximately 10
mCi for FTP, 15 mCi for PIB, and 5–10mCi for FDG. PET images were
acquired and reconstructed as previously described
(Ossenkoppele et al., 2016; Lehmann et al., 2013). We analyzed data
acquired from 50–70 min post-injection (PIB), 80–100 min post injec-
tion (FTP), and 30–60 min post-injection (FDG).
2.6. Neuroimaging preprocessing
MPRAGE images were segmented and parcellated using FreeSurfer
5.3 (surfer.nmr.mgh.harvard.edu). For cerebellar gray parcellation we
used the Spatially Unbiased Infratentorial (SUIT) atlas as previously
described (Maass et al., 2017; Desikan et al., 2006; Diedrichsen et al.,
2009).
PET frames were realigned, averaged and co-registered onto the
corresponding MRI. We calculated standardized uptake value ratio
(SUVR) images by dividing raw count maps by mean tracer binding in
speciﬁc reference regions (pons for FDG, inferior cerebellar gray matter
(GM) for FTP, and cerebellar GM for PIB) deﬁned on the MRI, as pre-
viously described (Maass et al., 2017; Ossenkoppele et al., 2016; La Joie
et al., 2017).
MRI was segmented into GM, white matter and cerebrospinal ﬂuid
using Statistical Parametric Mapping 12 (SPM12; Welcome Department
of Imaging Neuroscience, Institute of Neurology, London, UK) and
warped onto Montreal Neurological Institute (MNI) template space. We
then used the corresponding patient-speciﬁc deformation matrices to
warp the corresponding PET images to template space. Total
Intracranial Volume (TIV) (Malone et al., 2015) was derived from
SPM12 to be used in statistical analyses (see below).
2.7. Image analysis and assessments
All images were assessed qualitatively at the individual level by
visual inspection of each image by two visual raters (OHLS and GDR)
Table 2.
Control groups characteristics.
Control group FTP PET HC FDG PET HC MRI HC MRI HC by Potvin et-al* AD disease control group
Used for Tau PET w-maps, mean SUVR
comparison, group voxel-wise t-
test, and frequency maps analysis
Group voxel-wise t-
test analysis
Group voxel-
wise t-test
analysis
Individual atrophy level assessment Mean SUVR comparison, and
frequency map analysis
Inclusion criteria CDR 0, age range 20–95, negative
Aβ-PET, no RHI
Males, CDR 0, age
range 20–95 negative
Aβ-PET, no RHI
Males, CDR 0,
age range 20–95,
no RHI
Adopted from Potvin et-al 2017, an open
database of 2757 cognitively healthy
males and females, aged 18–94, 82%- W,
10% B, 7% A*
Meet NIA-AA criteria for AD
dementia or MCI, positive Aβ-
PET, no RHI
Recruited from Berkeley aging cohort study
(BACS) - volunteer based healthy
aging cohort
Aging cohort at UCSF
and BACS
Aging cohort at
UCSF
UCSF ADC cohorts
Number 67 30 54 22
Sex 55% males 100% males 100% males 23% males
Age (mean,
range)
66
(20–93)
64
(26–80)
66
(33–86)
64
(48–82)
Education (mean,
range)
17
(13–20)
17
(12–22)
17
(12–20)
17
(14–24)
Race 91% - W
6% - A
1.5% - M
1.5% - O
80% - W
3.3%-B
3.3% – M
13.3% - U
81.5% - W
1.8% - A
1.8% - O
14.8% - U
86.4 – W
4.5% - B
9.1% - U
MMSE (mean,
range)
29
(25–30)
29
(27–30)
29
(26–30)
21
(8–28)
ApoE status E3/3 74.5%
E3/4 12.7%
E2/3 12.7%
E3/3 70.4%
E3/2 3.7%
E3/4 25.9%
E3/3 57.4%
E3/4 25.9%
E2/2 1.8%
E2/3 11.1%
E4/4 3.7%
E3/3 28.6%
E3/4 52.4%
E4/4 14.3%
E2/4 4.8%
Amyloid PET
status
All negative All negative n/a n/a All positive
Abbreviations: HC – Healthy Controls; PET - Positron Emission Tomography; MRI - Magnetic Resonance imaging; MCI – Mild cognitive Impairment; SUVR -
Standardized Uptake Value Ratio; NIA-AA - National Institute on Aging Alzheimer's Association; Aβ – Amyloid beta; BACS – Berkeley Aging Cohort; UCSF -
University of California, San Francisco; MMSE - Mini-Mental State Examination; W - White; A - Asian; B – Black/African American; O - Other; U - Unreported; M -
Mixed; ApoE - Apolipoprotein E; n/a - not applicable; AD – Alzheimer's disease; TES – Traumatic Encephalopathy Syndrome; CDR – Clinical Dementia Rating;
FTP= ﬂortaucipir; FDG – ﬂudeoxyglucose.
* Potvin et-al, NeuroImage, 2017, doi:10.1016/j.neuroimage.2017.05.019.
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who were not blinded to clinical data. Group level comparisons with CN
(all imaging modalities) and AD (FTP only) were conducted using
voxelwise and region of interest (ROI) analyses.
2.7.1. Assessment of amyloid positivity
Individual native space PIB-SUVR images were rated as positive or
negative for cortical uptake by one of the visual raters (OHLS or GDR)
(Rabinovici et al., 2011). Global SUVR values were also converted to
centiloid values (see supplementary information for detailed descrip-
tion of the conversion and validation methods).
2.7.2. Assessment of FTP PET binding
2.7.2.1. Whole cortical and medial temporal lobe (MTL) mean
SUVR. Native space cortical and MTL mean SUVR were calculated for
all participants. Subject-speciﬁc cortical masks were prepared by
combining all relevant parcellated Freesurfer ROIs. Global mean
cortical SUVR was calculated as a weighted average across all cortical
ROIs. Since uptake in TES patients was dominant in the medial aspects
of the temporal lobe and since the MTL is known to accumulate tau
pathology in CTE, we also calculated a weighted mean SUVR of the
MTL, including bilateral FreeSurfer-deﬁned entorhinal and
parahippocampal cortices and amygdala. Hippocampus was not
included in the ROI to avoid spill over from nonspeciﬁc binding in
the adjacent choroid plexus.
2.7.2.2. Voxel-wise analysis of FTP binding. Group level analysis of FTP
binding was performed using FTP-PET SUVR images warped to MNI
space, masked by an average brain mask, and smoothed using a 4 mm
isotropic Gaussian kernel. TES patients were compared to CN (n=67,
Table 2) using a two-sample t-test voxelwise analysis, including age as a
covariate.
2.7.2.3. FTP w-score maps. To compute individual maps of abnormal
FTP binding while accounting for age-related non-speciﬁc changes in
brain FTP binding (Lowe et al.), voxelwise w-score (age-adjusted Z-
score) maps were computed for every patient based on the FTP control
group (n=67, Table 2 (La Joie et al., 2012)). The concept and method
of w-score calculation has been described in detail elsewhere (La Joie
et al., 2018). In brief, we ﬁrst ran a voxelwise regression model within
the control group to estimate the eﬀect of age on FTP binding. Based on
this regression, FTP binding in each voxel in each patient can be
attributed a w-score based on the normal control distribution. Control
participant w-maps were computed similarly but with a “leave one out”
method, meaning that each control was compared to the regression
model based on the other 66 controls. The resulting w-score map was
then thresholded at 1.645 (to represent the 95th percentile of a normal
distribution) and binarized, resulting in a subject-speciﬁc map of
abnormal voxels. The percentage of suprathreshold voxels in each
patient's segmented gray and white matter image was calculated. We
then computed group frequency maps by summing all thresholded and
binarized w-maps for every group (all TES, PIB-negative TES, CN, MCI-
AD and dementia-AD) and dividing the summed image by the number
of subjects in each group. Thus, the value in each voxel in the frequency
map represents the percentage of subjects in the group that have
abnormal binding (based on a threshold of w-score>1.645) in that
location.
To summarize, FTP-PET outcome measures are presented at the
individual and group levels. At the individual level, raw FTP SUVR
maps, voxel-based w-maps, percentage of abnormal voxels (w-
score>1.645) and mean cortical and MTL SUVR are presented. At the
group level, frequency maps and voxelwise analysis of the TES group as
a whole, as well as the amyloid-negative subgroup, are presented in
contrast with CN and patients with AD.
2.7.3. Assessment of MRI abnormalities
2.7.3.1. GM loss. Quantitative measures of regional cortical thickness,
volumes of subcortical structures, and ventricular volumes were
calculated against a normative data set described by Potvin et-al
(Potvin et al., 2017). This normative dataset includes 2757
cognitively healthy males and females, aged 18–94 from 23 samples,
provided by 21 independent research groups. Based on this dataset,
predicted values of thickness/volume as well as z-scores were
calculated for each TES patient assessing deviation from normality
while accounting for age, sex, estimated TIV, scanner manufacture and
magnetic ﬁeld strength (Potvin et al., 2017).
2.7.3.2. CSP size. CSP length and width were measured for every
patient by a radiologist (OHLS) that assessed the T1 images for a
CSF-ﬁlled cavity between the leaﬂets of the septum pellucidum and
then used the ITK-SNAP 2.4.0 annotation tool to measure CSP width (in
coronal sections) and length (in axial sections).
2.7.3.3. Voxelwise analyses. Voxelwise contrasts between TES and CN
(n=54, Table 2) were performed in SPM12. Modulated, GM
segmented images were warped to MNI space and smoothed to PET
resolution (by 7.6 FWHM isotropic Gaussian kernel). A two-sample t-
test model of SPM12 was implemented with age, scanner and estimated
TIV as covariates.
2.7.4. Assessment of metabolism patterns
Voxelwise group-level contrasts of FDG in TES vs CN (n=30,
Table 2) were performed using the FDG-PET SUVR images warped to
MNI space and smoothed by a 4 mm FWHM isotropic Gaussian kernel
(SPM12). Comparisons were made using a two-sample t-test, adding age
as a covariate.
2.8. Statistical analysis
Diﬀerences in demographic characteristics (age, education, MMSE)
between TES patients and CN or AD patients were assessed using the
Mann-Whitney U-test. For each voxelwise analysis (in all modalities
mentioned above), pairwise contrasts were performed and resulting T
maps were thresholded (based on uncorrected p<0.005 at the voxel
level with family wise error-corrected (fwe) p<0.05 at the cluster level)
and converted to eﬀect size Cohen's d maps using the CAT12 toolbox
(www.neuro.uni-jena.de/cat/). Maps were rendered on a 3D brain
surface using BrainNet Viewer (Xia et al., 2013) (www.nitrc.org/
projects/bnv/) using default interpolation.
3. Results
3.1. Patient's characteristics
Patient characteristics are summarized in Table 1. All eleven pa-
tients were exposed to RHI in sports; ten played American football,
including seven at the professional level in the U.S. National Football
League. All patients reported innumerable head impacts with between
none to multiple (40–50) concussions (deﬁned as head impact followed
by loss of consciousness or amnesia/neurologic symptom). Since self-
report estimates of concussions and sub-concussive blows are unreliable
(Register-Mihalik et al., 2013), we report cumulative years of sports
participation as a proxy (McKee et al., 2013; Mckee et al., 2018).
Neuropsychiatric complaints varied across patients, with memory loss
being the most common. Eight patients were diagnosed with mild
cognitive impairment (based on CDR of 0.5) and 3 with mild dementia
(CDR 1). Speciﬁc ages, race, ApoE genotypes, and positions played are
not shown in order to maintain anonymity. On cognitive testing, pa-
tients with TES as a group showed impaired list learning, moderate
memory diﬃculties, slightly slowed performance on a set shifting task,
and mild diﬃculty with confrontation naming. However, results were
highly variable across participants and overall less profound than def-
icits seen in MCI or dementia due to AD (Table 3, individual values of
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the TES cohort are presented in supplementary Table 1). The TES group
endorsed more depressive symptoms than controls and patients with
AD.
3.2. PIB-PET
Two of the patients with TES were PIB-positive on visual read and
quantitatively using centiloid values (12.2 threshold for positivity
(La Joie et al., 2019)). Patient 1 had diﬀuse cortical uptake and a
centiloid value of 53 (Fig. 1A), while patient 2 had focal areas of cor-
tical uptake in the left frontal lobe and left posterior cingulate and a
centiloid value of 16. Analyses of other imaging modalities were per-
formed ﬁrst for the whole TES group (PIB-positive and PIB-negative),
and again separately for the PIB-negative subgroup (excluding the two
amyloid-positive patients) in order to avoid the potential confound of
AD pathology on imaging ﬁndings.
3.3. FTP-PET
Fig. 1 shows FTP images of all patients with TES. Patient 1 (diﬀusely
PIB positive) exhibited diﬀuse, intense, cortical FTP uptake, with re-
lative sparing of sensorimotor and occipital cortex (Fig. 1B). Cortical
FTP w-scores were very high, reaching a maximum of 24 standard
deviations above age-matched controls, with 71% of gray and white
matter voxels classiﬁed as abnormal (Fig. 1B). This patient's mean
cortical and MTL SUVR values were higher than all other TES patients
or CN and fell within the range of patients with AD (Fig. 1C and D).
Patient 2 (focal PIB positive) had a similar pattern of diﬀuse cortical
FTP uptake, though with much lower intensity. W-score map showed
32.5% abnormally high voxels, mainly in temporal and frontal regions.
Mean cortical and MTL SUVR values were slightly above age-matched
controls, and in the lower range of AD patients (Fig. 1C and D). Patient
3 demonstrated uptake predominantly in temporal and frontal cortices,
with 28.7% of voxels classiﬁed as abnormal. This frontotemporal pre-
dominant binding pattern was also apparent in three other PIB negative
patients (patients 4–6). Global mean cortical binding in these cases was
within the CN range, and slightly higher in the MTL. Patient 7 showed a
“dot-like” pattern with a non-speciﬁc distribution of small clusters with
mildly elevated binding. 10.5% of voxels were classiﬁed as abnormal.
The dot-like pattern was also apparent in Patient 8 and in various
control subjects that did not report head injury exposure (Fig. 2). Pa-
tients 9–11 did not show any clear region of elevated binding, with only
0.1–1.9% of voxels classiﬁed as abnormal. Mean global cortical and
MTL SUVRs were in the range of CN for patients demonstrating either
non-speciﬁc “dot-like” binding or no elevated binding.
FTP frequency maps revealed that up to 60% (7/11) of TES patients
demonstrated supra-threshold FTP binding, mainly in the bilateral
frontotemporal cortex, with additional foci in the medial and lateral
parietal lobes (Fig. 3A). Restricting the analysis to PIB-negative patients
only, a similar but more restricted frontotemporal pattern persisted
with reduction in parietal signal. In contrast, w-score frequency maps of
CN showed small and irregularly distributed clusters of abnormal
voxels reaching a maximum of only 12% (8/67) of the group in any
voxel. Frequency maps of patients with MCI due to AD reveal a more
diﬀuse pattern of abnormality with most (8–9/9) patients with MCI due
to AD demonstrating elevated binding in the temporal and parietal
lobes, with variable involvement of frontal cortex. Patients with de-
mentia due to AD showed the most diﬀuse pattern of abnormal binding,
with all (13/13) patients showing abnormal binding in temporal, par-
ietal and frontal cortices, sparing only primary unimodal cortices.
On voxelwise contrast with CN, patients with TES showed elevated
FTP binding predominantly in the left inferior-posterior temporal lobe
with medium to strong eﬀect size (Cohen's d up to 1.1). When re-
stricting the analysis to the PIB-negative subgroup, a more constricted
region of elevated binding was seen in the left inferior temporal lobe
with additional region of increased binding in the inferior frontal lobes
Table 3
Neurocognitive assessments.
TES
(n=11)
MCI due to AD
(n=9)
Dementia due to AD
(n=13)
Controls normative data
Age 59±13.6 65.4± 10.7 62.5± 9.5 50-64#
Episodic memory
CVLT CVLT learning (sum of 4 trials) 20.6± 5.8⁎⁎ 19.3± 3* 16.6± 5.2⁎⁎ 23-29$
Correct 30’’ 5.1± 2.6⁎⁎ 4.1± 2.1⁎⁎ 2.2±2.0⁎⁎ 8.2± 1.4
Correct 10’ 4.1± 3.1⁎⁎ 2±2.6⁎⁎ 1.4±2⁎⁎ 7.8± 1.4
Cued Correct 5.0± 2.8⁎⁎ 3.4± 2.9⁎⁎ 1.7±1.8⁎⁎ 8.1± 1.2
Benson Figure recall Benson Figure 10’ recall 8.8± 2.8⁎⁎ 2.7± 3.0⁎⁎ 4.4±3.6⁎⁎ 12.6±2.3
Executive functioning
Digits Forward 6.1± 1.4* 5.9± 1.3 5.6±1.4* 7.2± .9
Digits Backward 4.1± 1.2 4.0± 1.4 3.3.0± 1.4⁎⁎ 5.4± .1.3
Stroop Color Naming 66.5± 21.2⁎⁎ 49.6± 25.8⁎⁎ 44.1± 18.2⁎⁎ 90.3±12.9
Stroop Inhibition 40.1± 29.4* 23.8± 12.2⁎⁎ 17±12.9⁎⁎ 52.6±9.6
Modiﬁed Trails Time 39.7± 17.2* 67.7± 37.4⁎⁎ 106±27.9⁎⁎ 26.8±10.7
Design Fluency 8.8± 3.7 6.5± 4.4⁎⁎ 4.2±1.8⁎⁎ 11.4±2.8
Lexical Fluency 12.3± 4.4 11.6± 3.4* 8.6±5.3⁎⁎ 15±3.9
Semantic Fluency 17.5± 7.8* 13.8± 4.8⁎⁎ 10.6± 7.2⁎⁎ 22.7±4.7
Language
Boston naming total correct 12.8± 1.4⁎⁎ 13.3± 1.5* 11.1± 3.4⁎⁎ 14.5± .9
Visuospatial skills
Benson Figure Copy 15.6± .9 11.4± 3.9⁎⁎ 11.8± 4.9⁎⁎ 15.5±1.1
Mood
Geriatric Depression Scale 10.8± 7.2* 3.8± 2.8 8.7±6 0-9 normal; 10-19 mild; 20-30 severe
Values in the table represent mean± standard deviation; Z-scores were computed compared to normative data and are marked with asterisk: *=−1.5≤ z-score≤
−1.1; **=z-score ≤ −1.6
# Controls normative data presented in the table are for ages 50–64 and education ≤16 years, CVLT normative values are presented for the age range of 60–69.
$ Range of normal values. No standard deviation available.
Abbreviations: AD – Alzheimer's disease; TES – Traumatic encephalopathy syndrome; CN – cognitively normal; CVLT - California verbal learning test
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(Fig. 3B). No region of elevated binding was seen in TES patients
compared with patients with MCI or dementia due to AD (supplemen-
tary ﬁgure 1), while many cortical regions showed higher binding in
MCI/dementia due to AD compared with TES (supplementary ﬁgure
and Fig. 3A).
3.4. Structural MRI
TES patients showed heterogeneous patterns of MRI GM loss
(Fig. 4A and C). Some patients demonstrated cortical thinning (w-
score<−1) compared to matched controls, some demonstrated mainly
subcortical gray matter volume loss, and others did not show clear
atrophy (w-score>−1). On average, the hippocampus showed the
most severe volume loss (Fig. 4C). Eight of eleven patients had a CSP,
with width ranging between 3 and 11 mm and length ranging between
1.5 and 45 mm (Fig. 4B). On voxelwise contrasts with CN, patients with
TES showed lower GM volumes in the lateral and medial frontal cor-
tices, insula and anterior temporal lobes (Cohen's d up to 1.5). This
pattern was constrained to a smaller area when restricting the analysis
to the PIB-negative subgroup (Fig. 4D).
3.5. FDG-PET
Six patients underwent FDG-PET in addition to amyloid- and tau-
PET. Individual FDG SUVR images revealed primarily frontotemporal
hypometabolism in addition to various degrees of parietal involvement.
Patient 8 showed normal FDG uptake (Fig. 5A). As a group, patients
with TES had signiﬁcantly reduced metabolism mainly in the fronto-
temporal cortices with some parietal (precuneus and angular/supra-
marginal) involvement compared with CN (Cohen's d eﬀect size up to
2.2). When restricting the analysis to the ﬁve PIB-negative patients that
have FDG-PET (excluding patient 2), the frontotemporal cluster re-
mained signiﬁcant with large eﬀect size (Cohen's d up to 2.1, Fig. 5B).
4. Discussion
In this study we applied multi-modal imaging to detect brain injury
and molecular pathology in highly phenotyped patients meeting TES
criteria who are at risk for CTE pathology. Tau-PET signal was highly
elevated only in amyloid-positive patients, with more subtle uptake
seen in a subset of amyloid-negative individuals, particularly in the
frontal and temporal cortices. MRI and FDG changes were hetero-
geneous but tended to converge in frontotemporal regions. In summary,
Fig. 1. Amyloid and tau PET patterns in TES, individual patterns.
Aβ (PIB)-PET visual read, centiloid value, and SUVR images (A); Tau (FTP)-PET SUVR images, w-score images, and percentage of voxels with w-score>1.645 (B).
Mean FTP-SUVR (C) and medial temporal lobe mean SUVR (D) in patients with TES (black triangles – PIB-positive; black circles – PIB-negative), patients with MCI
(red circles black outline) or dementia due to AD (red circles no outline) and healthy controls (blue circles). The patient number on the left corresponds to the patient
number in Table 1.
Images are presented in neurological convention (left of the image is the left side of the patient). Abbreviations- Pt= Patient; TES= traumatic encephalopathy
syndrome; PIB=Pittsburgh compound B; PIB+=positive visual read, PIB-= negative visual read; FTP= ﬂortaucipir; MTL=medial temporal lobe;
SUVR= standardized uptake value ratio; W-score= age adjusted z-score.(For interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article.)
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multi-modal imaging provides evidence for frontotemporal-pre-
dominant neurodegeneration and molecular pathology (tau more than
amyloid) in individuals with TES, in line with the cognitive and beha-
vioral deﬁcits reported in this disorder.
Group-level elevated frontotemporal FTP binding was seen using
both frequency maps and voxelwise analysis when comparing the entire
TES cohort (n=11) or the amyloid-negative subgroup (n=9) to CN.
An extensive and intense FTP binding pattern was observed in the
amyloid-positive patients (patients 1 and 2), possibly due to primary
AD pathology, with or without co-morbid CTE. The intensity of binding
was lower in amyloid-negative patients with TES compared to patients
with MCI or dementia due to AD. Four amyloid-negative patients with
TES (patients 3–6) showed visually discernable and conﬂuent regions of
elevated FTP signal, predominantly in frontal and temporal cortices,
Fig. 2. Tau (FTP) PET “dot-like” pattern in TES patients and in CN
FTP SUVR (A) and w-score (B) images of two patients (patients 7 and
8) and four control subjects that have a non-speciﬁc distribution of
small clusters with mildly elevated binding.
Abbreviations: FTP= ﬂortaucipir; TES= traumatic encephalopathy
syndrome; CN – cognitively normal control; Pt. – patient; Ctrl. –
control; SUVR - standardized uptake value ratio; W-score= age ad-
justed z-score.
Fig. 3. Tau (FTP) PET in TES compared with CN and AD, group analysis
FTP binding frequency maps of the TES cohort (n=11), the amyloid-negative subgroup of TES patients (n=9), healthy controls (n=67), patients with dementia
due to AD (n=13) and patients with MCI due to AD (n=9). The value in each voxel represents the percentage of subjects that have high binding (deﬁned here as w-
score > 1.645) in that voxel (A). Voxelwise two sample t-test analysis reported in Cohen's d eﬀect size of FTP-PET binding in the TES cohort (n=11) and in the
amyloid-negative subgroup of TES patients (n=9) compared with 67 healthy controls, PUncorrected < 0.005 in the voxel level, Pfwe < 0.05 in the cluster level (B).
Images are presented in neurologic convention. PIB= Pittsburg compound B; FTP= ﬂortaucipir; Lat= lateral; Med=medial; Inf= inferior; TES – traumatic en-
cephalopathy syndrome; AD=Alzheimer's disease; MCI=mild cognitive impairment; CN – cognitively normal control; CDR= clinical dementia score; FWE –
family wise correction.
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including the medial temporal lobe. In the absence of amyloid, this
signal may be related to CTE tau pathology, with the distribution of
binding consistent with CTE neuropathological stages III-IV
(McKee et al., 2013). However, we cannot exclude the possibility that
FTP is binding to an alternative form of tau (e.g. primary age-related
tauopathy, or other non-AD tau isoforms (Smith et al., 2017;
Schonhaut et al., 2017; Utianski et al., 2018)), or to non-tau related
processes in these individuals, given some of the questions about tracer
speciﬁcity (see limitations). Two amyloid-negative patients showed a
“dot-like” pattern of binding, which could be consistent with the focal
tau deposits seen in CTE stages I-II but was also seen in normal controls
with no RHI. The remaining three patients showed no evidence of ab-
normal binding. These results may be due to an absence of CTE pa-
thology in these individuals, or to lack of sensitivity of FTP-PET for
detecting early stages of CTE.
All the amyloid-negative patients in our cohort demonstrated low
FTP binding compared with patients with MCI or dementia due to AD.
There are several potential interpretations of this ﬁnding. First, the low
level of binding may be explained by a low burden of tau pathology. As
our patient group is relatively small and consists of mostly young
(median age of 64) and mildly impaired (CDR 0.5–1) patients, it is
possible that some of them have early stage CTE bearing a low density
of tau-positive aggregates. Others may have neuropathological pro-
cesses other than tau underlying their symptoms. Additionally, it is
possible that FTP may bind with weaker aﬃnity to tau aggregates in
CTE than in AD. Tau aggregates in CTE are similar, though not iden-
tical, to those seen in AD. Neuronal inclusions include paired helical
ﬁlaments of hyper-phosphorylated tau composed of a mix of 3-repeat
and 4-repeat tau isoforms, reﬂecting alternative splicing of the micro-
tubule binding motif on exon 10, though the biochemical composition
may be slightly skewed toward 4R isoforms in CTE compared to AD.
CTE also features more axonal pathology and prominent astrocytic tau
Fig. 4. Individual and group-level analysis of
structural changes in TES patients
Axial T1 weighted MRI of all 11 patients with
TES (A) including cavum Septum Pellucidum
(CSP) width and length in millimeters (B).
Individual atrophy patterns as represented by
w-scores of bilateral cortical thickness, sub-
cortical gray matter volume, bilateral hippo-
campal volume, and ventricular volume com-
pared to normalized control data (based on
Potvin et-al (Potvin et al., 2017)) (C). Group-
level two sample t-test analysis of atrophy
patterns (PUncorrected < 0.005 at the voxel
level, Pfwe < 0.05 at the cluster level converted
to Cohen's d eﬀect size) in the whole TES co-
hort (n=11) and the amyloid-negative sub-
group only (n=9) compared with 54 controls.
Patient numbers correspond to the same num-
bers as in Table 1 and in the other ﬁgures.
TES – traumatic encephalopathy syndrome; CN
– cognitively normal control; CSP – cavum
septum pellucidum; GM – gray matter; Lt – left;
Rt – right; Vol – volume; Pt – patient; FEW –
family wise error corrected.
Fig. 5. Individual and group-level metabolism pattern
FDG-PET SUVR images of six patients with TES that underwent FDG-
PET (A) and voxelwise two sample t-test analysis of the all patients
and the ﬁve amyloid-negative patients compared with 30 controls.
Reported in Cohen's d eﬀect size, Puncorrected<0.005; cluster
threshold: Pfwe<0.05 (B). Patient numbers correspond to the same
numbers as in Table 1 and in the other ﬁgures.
FDG – ﬂuorodeoxyglucose; SUVR - standardized uptake value ratio;
TES – traumatic encephalopathy syndrome; CN – cognitively normal
control; FEW – family wise error correction.
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inclusions, which are not a feature of AD (McKee et al., 2013). More-
over, it has been recently shown that the β-helix conformation of tau
aggregates in CTE is distinct from other taupathies (Falcon et al., 2019).
These diﬀerences in biochemical composition, post-translational mod-
iﬁcations and microstructure could lead to a reduced detectability by
routine tau CSF assays (Alosco et al., 2018) as well as reduced aﬃnity of
FTP to bind to tau aggregates in CTE. This possibility is supported by
preliminary autoradiography data showing at least a 5-fold lower in-
tensity of FTP binding in temporal cortex of stage III-IV CTE brain
sections compared with AD brain sections (HAI-Book). Other studies
have found lower FTP in vivo retention (Smith et al., 2017;
Schonhaut et al., 2017; Utianski et al., 2018; Cho et al., 2017) and no or
low autoradiography binding (Marquié et al., 2015; Sander et al., 2016;
Lowe et al., 2016) in non-AD tauopathies, such as progressive supra-
nuclear palsy, corticobasal degeneration and Pick's disease. Ultimately,
correlational studies between FTP-PET and autopsy in the same in-
dividuals will be needed to narrow down these possibilities.
It has been recently shown that symptomatic former National
Football League (NFL) players have higher FTP-PET binding in bilateral
superior frontal, bilateral MTL and left parietal regions in the group
level but individual binding levels overlap with binding in CN
(Stern et al., 2019). Consistent with these ﬁndings, our group frequency
maps demonstrate increased frontotemporal binding in a subset of at-
risk patients. Previous case reports utilizing FTP imaging in patients at
risk for CTE showed either striatal and nigral binding (Mitsis et al.,
2014) or weak binding in the gray matter – white matter (GM-WM)
interface (Dickstein et al., 2016). In our cohort, we also found striatal,
nigral, and GM-WM matter interface FTP binding, but these were nei-
ther unique to nor more prominent in patients with TES compared with
controls. Accordingly and based on other studies (Marquié et al., 2017),
we interpret the striatal and nigral binding as “oﬀ-target” signal un-
related to tau. Also, though part of the signal we see in GM-WM in-
terface may be detecting early CTE lesions, our data suggest that this
signal is indistinguishable from noise. Other in-vivo studies using a
diﬀerent putative tau ligand, [18F]FDDNP PET, demonstrated distinct
binding patterns in patients at risk for CTE compared to controls
(Barrio et al., 2015, Small et al., 2013). However, [18F]FDDNP appears
to be a non-selective tracer with aﬃnity for β-pleated sheets composed
of various aggregated proteins, including tau but also Aβ, prion protein,
huntingtin and others (Smid et al., 2006). Additional limitations of
[18F]FDDNP include low signal-to-noise, and poor reproducibility of
results across sites (Ossenkoppele et al., 2012).
Our results may indicate that early stages of CTE pathology are
below the sensitivity of FTP-PET. Small numbers of low volume pa-
thological foci are seen neuropathologically at early stages of CTE.
These foci, estimated to be 1–5 mm in diameter in early disease stages
(Mez et al., 2017; McKee et al., 2013), may be too small to detect given
the limited spatial resolution of PET. In comparison, the resolution of
our PET scanner (Siemens Biograph 6 Truepoint PET-CT scanner) is
6.5× 6.5×7.25 mm (calculated based on phantom (Joshi et al.,
2009)). Moreover, due to the heterogeneity of head impacts, the loca-
tion of tau varies across individuals at early disease stages. This het-
erogeneity becomes less pronounced in later stages as the disease pro-
gresses and the lesions become larger and more conﬂuent, notably in
the frontal and temporal cortices (McKee et al., 2013), likely facilitating
their detection by molecular imaging.
Two patients in our series were PIB and tau PET positive (patients 1
and 2). This combination of amyloid and tau PET positivity may be
attributed to primary AD pathology with or without co-morbid CTE,
speciﬁcally for patient 1 that had extensive and intense binding of both
amyloid and tau PET (La Joie et al., 2012). The focal amyloid positivity
pattern together with the lower FTP binding seen in patient 2 may re-
present either early AD changes, CTE pathology with Aβ accumulation
following trauma, or incidental/age-related amyloid positivity. Neuro-
pathological studies have reported the presence of amyloid beta plaques
both in the acute phase after a single severe traumatic brain injury
(Roberts et al., 1991; Roberts et al., 1994; Ikonomovic et al., 2004) and
in the chronic phase following RHI (Mez et al., 2017; McKee et al.,
2013; Stein et al., 2015). In the acute phase, a rapid and usually focal
accumulation of Aβ plaques was shown in up to 30% of patients, in-
cluding children, who died acutely following severe TBI (Roberts et al.,
1991; Roberts et al., 1994). In the chronic phase, recent series have
reported that 52–61% (Stein et al., 2015; Mez et al., 2017) of patients
with autopsy-proven CTE also have amyloid plaques (Mez et al., 2017;
Stein et al., 2015). The plaques observed following TBI are similar but
not identical to the ones deposited in AD. In AD, the plaques are more
commonly neuritic, while post-TBI plaques are typically diﬀuse. The
proportion of amyloid positivity in our series was smaller (2/11)
compared to neuropathological reports (Stein et al., 2015; Mez et al.,
2017). This discordance may be explained by small sample size, the
relatively young age of our cohort, or possibly lower aﬃnity of PIB for
diﬀuse versus neuritic plaques (Seo et al., 2017; Ikonomovic et al.,
2008).
We found variability in the presence and size of CSP and the degree
of gray matter atrophy across patients. Our ﬁndings are in line with
reported imaging ﬁndings in 100 boxers showing hippocampal atrophy
in 59%, cerebral atrophy in 24%, ventricular size abnormalities in 19%,
and CSP in 43% of patients (Orrison et al., 2009). Among the six pa-
tients who underwent FDG-PET, ﬁve showed hypometabolism in the
temporal lobe and four had additional frontoparietal hypometabolism.
These ﬁndings are consistent with a previous report from our group that
demonstrated temporal hypometabolism in ﬁve retired National Foot-
ball League players (Gardner et al., 2015) and other reports of similar
patterns of hypometabolism in boxers (Provenzano et al., 2010) and
war veterans with blast exposure (Peskind et al., 2011).
At the group level, we found a frontotemporal predominant ab-
normality pattern across neuroimaging modalities. Such an abnormality
pattern is in line with the cognitive and behavioral predominant clinical
presentation seen in our series and described in TES, suggesting an
association between brain injury, tau binding, neurodegeneration (as
expressed by atrophy and hypometabolism) and neuropsychiatric
symptomatology. The extent and eﬀect size, however, diﬀer between
modalities with FDG hypometabolism having the most widespread
pattern and highest eﬀect size (Cohen's d up to 2.2), followed by MRI
atrophy measures, and then FTP binding (Cohen's d < 1.5 and 1.1 re-
spectively). Atrophy and hypometabolism are considered to be down-
stream of tau deposition as well as other pathologies (i.e. axonal injury,
cerebrovascular disease and other causes of white matter injury, or
other proteinopathies). As such, MRI and FDG measures reﬂect the
collective eﬀects of all pathologies and may thus be more sensitive to
trauma-related injury, though non-speciﬁc regarding the underlying
mechanism of injury.
Strengths of this study include the application of multimodal neu-
roimaging utilizing both structural and molecular imaging in highly
phenotyped patients meeting TES criteria, the comparison to a CN
group as well as patients with AD (for FTP-PET), and the application of
both individual and group-level analyses. Our study has limitations.
The relatively small number of patients that reduces power for statis-
tical analysis. It is possible that with more patients, larger variability in
the amyloid negative tau-PET binding levels would have been seen, and
together with higher statistical power uncover earlier stages of CTE
pathology. Additional limitations include the lack of neuropathological
validation, and the use of multiple control groups, some of which in-
cluded both males and females while the TES group consists of males
only. In a recent paper (Buckley et al., 2019) no clear association was
found between sex and regional tau deposition in amyloid negative
cognitively normal individuals. Thus, the inclusion of female controls is
unlikely to have signiﬁcantly impacted our results. Detailed athletic
characteristics including age at ﬁrst exposure were not assessed with a
standard protocol in this retrospective study, and thus are not reported.
Furthermore, due to varying acquisition protocols, we were not able to
include diﬀusion tensor imaging (DTI), a sensitive imaging modality to
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assess TBI-related white matter injury, in our MRI assessment. The
speciﬁcity of FTP is challenged by binding in areas that are known to
have minimal or no neuroﬁbrillary tangles such as basal ganglia,
choroid plexus, meninges, and cerebrovascular lesions (Lockhart et al.,
2017; Bruinsma et al., 2017; Lee et al., 2018), as well as cortical binding
in clinical syndromes, such as semantic variant primary progressive
aphasia, that are usually caused by non-tau proteinopathies (Bevan-
Jones et al., 2017; Makaretz et al., 2017). Nevertheless, we found FTP
binding in frontotemporal regions in a distribution that is consistent
with the neuropathology of CTE.
5. Conclusion
In this case series of eleven patients with TES at risk for CTE, we
found a frontotemporal predominant pattern of brain injury at the
group level across modalities. FTP binding in amyloid-negative patients
was modest, predominantly aﬀecting the temporal and frontal lobes in
a subset of patients, potentially mirroring the distribution of pathology
in CTE pathologic stages III-IV. FTP may detect tau pathology in CTE,
though possibly in later stages of disease and with weaker binding
compared with AD. Correlation with post-mortem ﬁndings and larger
cohorts are needed to validate these ﬁndings.
Statistical analyseswere conducted by Orit Lesman-Segev, MD,
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